Anoro Ellipta 62.5 ug/1 (Umeclidinium Bromide and Vilanterol Trifenatate POWDER) 62.5 ug/1

Anoro Ellipta 62.5 ug/1 is a combination medication used for maintaining and improving lung function in chronic obstructive pulmonary disease (COPD). This inhaler contains umeclidinium bromide and vilanterol trifenatate, designed for respiratory administration.

Strength

62.5 ug/1

Pack Size

1 TRAY in 1 CARTON (0173-0869-10) / 1 INHALER in 1 TRAY / 30 POWDER in 1 INHALER

Manufacturer / TM Owner

GlaxoSmithKline LLC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Anoro Ellipta 62.5 ug/1 is primarily used for the long-term management of chronic obstructive pulmonary disease (COPD). This medication helps to relax the muscles around the airways, making it easier to breathe. It is often prescribed to individuals with COPD to improve lung function and reduce symptoms such as wheezing and shortness of breath. The combination of umeclidinium bromide and vilanterol trifenatate works together to provide effective relief for those suffering from this chronic condition.

Side Effects

Common effects of Anoro Ellipta 62.5 ug/1 may include dry mouth, throat irritation, and coughing. Some users might experience headaches or dizziness. These effects are generally mild and temporary, but if they persist or worsen, it is important to consult a healthcare provider. The medication is designed to provide relief from COPD symptoms, but individual responses can vary.

Precautions & Warnings

Anoro Ellipta 62.5 ug/1 should be used as directed by a healthcare professional. It is important to follow the prescribed dosage and administration instructions to avoid potential side effects. This medication should not be used by individuals with certain medical conditions, such as severe asthma or allergies to any of its components. Always store the inhaler properly and keep it out of reach of children.

Avoid Interactions

Anoro Ellipta 62.5 ug/1 may interact with other medications, including beta-blockers, anticholinergics, and certain antibiotics. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and other respiratory depressants should be used with caution while using this medication. Always consult a healthcare professional before starting any new medication.

References

Frequently Asked Questions

Anoro Ellipta 62.5 ug/1 is used for the long-term management of chronic obstructive pulmonary disease (COPD) to improve lung function and reduce symptoms.

Anoro Ellipta 62.5 ug/1 is administered via inhalation using the provided inhaler. Follow the instructions provided by your healthcare professional for proper use.

Common side effects may include dry mouth, throat irritation, coughing, headaches, and dizziness. These effects are usually mild and temporary.

Anoro Ellipta 62.5 ug/1 may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Anoro Ellipta 62.5 ug/1 should not be used by individuals with severe asthma or allergies to its components. Always consult a healthcare professional before use.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.